Dynamic Purchasing System for Pharmaceuticals

Supply of pharmaceuticals for a dynamic purchasing system (DBS) with an estimated total demand of 60,000,000 units. The DBS includes cardiac drugs such as Adenosine Injection (active ingredient Adenosine 6 MG/2ML) with a total estimated demand of approx. 31,010 ampoules (AM) and a 2021 demand of approx. 30,210 AM, Amlodipine Tablets (active ingredient Amlodipine 5 MG) with a total estimated demand of approx. 907,000 pieces (EA) and a 2021 demand of approx. 2,400 EA, Cafedrine and Theodrenaline Hydrochloride Injection (active ingredient 1 Cafedrine 200 MG, active ingredient 2 Theodrenaline 10 MG) with a total estimated demand of approx. 111,002 AM and a 2021 demand of approx. 47,562 AM, Candesartancilexetil Tablets (active ingredient Candesartan 16 MG divisible) with a total estimated demand of approx. 1,730,176 EA and a 2021 demand of approx. 0 EA, Metoprololsuccinate Extended-Release Tablets (active ingredient Metoprolol 39.91 MG divisible) with a total estimated demand of approx. 481,540 EA and a 2021 demand of approx. 5,100 EA, Ramipril Tablets (active ingredient Ramipril 2.5 MG) with a total estimated demand of approx. 804,180 EA and a 2021 demand of approx. 0 EA, and Ramipril Tablets (active ingredient Ramipril 10MG) with a total estimated demand of approx. 168,200 EA and a 2021 demand of approx. 3,600 EA. Antiemetics include Dimenhydrinate Injection (active ingredient Dimenhydrinate 62 MG) with a total estimated demand of approx. 31,220 AM and a 2021 demand of approx. 29,040 AM, Dimenhydrinate Injection (active ingredient Dimenhydrinate 100 MG, active ingredient 2 Benzyl alcohol 105 MG) with a total estimated demand of approx. 17,524 AM and a 2021 demand of approx. 12,000 AM, Dimenhydrinate Tablets (active ingredient Dimenhydrinate 50 MG) with a total estimated demand of approx. 1,700,000 EA and a 2021 demand of approx. 1,940 EA, and Ondansetron Hydrochloride Injection (active ingredient Ondansetron 4 MG) with a total estimated demand of approx. 46,485 AM and a 2021 demand of approx. 12,025 AM. Ophthalmics include Acetazolamide Tablets (active ingredient Acetazolamide 250 MG) with a total estimated demand of approx. 93,930 EA and a 2021 demand of approx. 90,130 EA, Dexpanthenol Ointment (active ingredient Dexpanthenol 50 MG) with a total estimated demand of approx. 157,132 tubes (TU) and a 2021 demand of approx. 27,930 TU, Sodium Chloride Solution (active ingredient Sodium Chloride 4.5 GM) with a total estimated demand of approx. 19,848 bottles (BT) and a 2021 demand of approx. 6,648 BT, and Oxybuprocaine Hydrochloride Eye Drops (active ingredient Oxybuprocaine 4 MG) with a total estimated demand of approx. 24,513 BT and a 2021 demand of approx. 19,970 BT. Dermatologicals include Aciclovir Cream (active ingredient Aciclovir 50 MG/G) with a total estimated demand of approx. 32,090 TU and a 2021 demand of approx. 522 TU, Dexpanthenol Eye and Nasal Ointment (active ingredient Dexpanthenol 50 MG/G) with a total estimated demand of approx. 157,132 TU and a 2021 demand of approx. 27,930 TU, Fat Cream for the treatment of skin diseases on dry skin (active ingredient Fatty acids, unsaturated 8.15 MG) with a total estimated demand of approx. 27,413 TU and a 2021 demand of approx. 2,040 TU, and Miconazole Nitrate Fluprednidene Cream (active ingredient 1 Miconazole 1 MG, active ingredient 2 Fluprednidene 0.9 MG) with a total estimated demand of approx. 15,023 TU and a 2021 demand of approx. 4,890 TU. Gastrointestinal therapeutics include Loperamide Hydrochloride Capsules (active ingredient Loperamide 1.860 MG) with a total estimated demand of approx. 851,473 EA and a 2021 demand of approx. 260,200 EA, Magaldrate Suspension (active ingredient Magaldrate 1600 MG) with a total estimated demand of approx. 198,570 BG and a 2021 demand of approx. 0 BG, Pantoprazole Sodium Tablets (active ingredient Pantoprazole Sodium-1.5-water 45.110 MG) with a total estimated demand of approx. 7,512,528 EA and a 2021 demand of approx. 46,020 EA, and Simethicone Chewable Tablets (active ingredient Dimethicone 40 MG) with a total estimated demand of approx. 274,260 EA and a 2021 demand of approx. 0 EA. Cold remedies include Cetylpyridinium Chloride and Benzocaine Lozenges (active ingredient 1 Cetylpyridinium 1.4 MG, active ingredient 2 Benzocaine 10 MG) with a total estimated demand of approx. 5,917,888 EA and a 2021 demand of approx. 24,480 EA, Myrtol Capsules (active ingredient Myrtol 300 MG) with a total estimated demand of approx. 2,593,640 EA and a 2021 demand of approx. 48,400 EA, and Acetylcysteine Tablets (active ingredient Acetylcysteine 600 MG) with a total estimated demand of approx. 558,430 EA and a 2021 demand of approx. 72,680 EA. Bronchodilators-Antiasthmatics include Codeine Phosphate Tablets (active ingredient Codeine 22.1 MG) with a total estimated demand of approx. 153,118 EA and a 2021 demand of approx. 50,400 EA, Ipratropium Bromide Solution for a nebulizer (active ingredient Ipratropium Bromide 0.25 MG) with a total estimated demand of approx. 47,902 AM and a 2021 demand of approx. 36,420 AM, and Salbutamol Aerosol (active ingredient Salbutamol 1.25 MG) with a total estimated demand of approx. 178,150 EA and a 2021 demand of approx. 73,350 EA. Antifungals include Bifonazole Cream (active ingredient Bifonazole 10 MG) with a total estimated demand of approx. 10,000 TU and a 2021 demand of approx. 0 TU, Itraconazole Capsules (active ingredient Itraconazole 100 MG) with a total estimated demand of approx. 24,080 EA and a 2021 demand of approx. 1,190 EA, and Terbinafine Hydrochloride Cream (active ingredient Terbinafine 10 MG) with a total estimated demand of approx. 10,561 TU and a 2021 demand of approx. 3,638 TU. Oral and pharyngeal therapeutics include Chlorhexidine Digluconate Solution (active ingredient Chlorhexidine 1.13 MG) with a total estimated demand of approx. 23,190 BT and a 2021 demand of approx. 90 BT, and Chlorhexidine Digluconate Gel (active ingredient Chlorhexidine Digluconate 10 MG) with a total estimated demand of approx. 1,890 TU and a 2021 demand of approx. 90 TU. Diuretics include Furosemide Sodium Infusion (active ingredient Furosemide 250 MG/25ML) with a total estimated demand of approx. 4,278 AM and a 2021 demand of approx. 1,680 AM, Furosemide Sodium Injection (active ingredient Furosemide 20 MG/2ML) with a total estimated demand of approx. 121,870 AM and a 2021 demand of approx. 53,950 AM, Furosemide Sodium Injection (active ingredient Furosemide 40 MG/4ML) with a total estimated demand of approx. 26,040 AM and a 2021 demand of approx. 25,680 AM, and Hydrochlorothiazide Tablets (active ingredient Hydrochlorothiazide 12.5 MG) with a total estimated demand of approx. 480,000 EA and a 2021 demand of approx. 0 EA. Additionally, Clonazepam Injection with a total estimated demand of approx. 38,950 AM and a 2021 demand of approx. 36,870 AM is procured. Existing DBS for antibiotics, antidotes, corticoids, narcotics, analgesics, and anticoagulants will be terminated prematurely on 31.12.2021 and transferred to this DBS on 01.01.2022.

Tender documents

Additional details